Clinical trial · Interventional
Adjuvant Radiotherapy in Patients With Early Endometrial Cancer
A Multicenter, Randomized, Controlled Trial of Adjuvant Radiotherapy in Patients With Early Endometrial Cancer Based on Moderate Risk Molecules Classification
NCT04956601CI-TRIAL-00052625not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare the effect of vaginal brachytherapy as adjuvant treatment after operation when compared to pelvic external beam radiotherapy in patients with early endometrial cancer based on moderate risk molecules classification.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
| Pathology | — | UNRESOLVED | — |
| Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| vaginal brachytherapy/pelvic external beam radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- VBT
- description
- CT image guided high-dose-rate vaginal brachytherapy, 30Gy/6f, 2f/w.
- interventionNames
- Radiation: vaginal brachytherapy/pelvic external beam radiotherapy
- type
- ACTIVE_COMPARATOR
- label
- EBRT
- description
- Pelvic external beam radiotherapy，IMRT/VAMT，IGRT suggested，DT 45Gy/25f.
- interventionNames
- Radiation: vaginal brachytherapy/pelvic external beam radiotherapy
Primary outcomes (1)
- measure
- DFS
- timeFrame
- 5-year
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Endometrial adenocarcinoma is confirmed by pathology, and the molecular types were microsatellite instability type and low copy type; 2. Stage IA and grade 3 or stage IB (FIGO 2009), without substantial lymph-vascular space invasion; 3. Surgery must have included a hysterectomy and bilateral adnexectomy. Pelvic lymph node sampling and para-aortic lymph node sampling are optional; 4. ECOG score is 0-2; 5. The interval time between surgery and radiotherapy is no more than 8 weeks; 6. The routine blood examination was normal; 7. Compliance is good and informed consent is voluntarily signed. Exclusion Criteria: 1. The patients receive chemotherapy; 2. History of previous malignant disease; 3. Previous diagnosis of Crohn's disease or ulcerative colitis.
References
Publications (0)
Data not yet available
No reference posted for this study.